Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Walgreens Boots Alliance, Inc. operates as a global pharmacy-led health and wellbeing company, with a significant presence in the U.S. and Europe. The company's competitive position is bolstered by its extensive retail pharmacy network, which includes over 9,000 locations in the U.S. and partnerships with health systems to provide integrated healthcare services.
Walgreens generates revenue primarily through retail pharmacy sales, which include prescription drugs and over-the-counter products. The company leverages its extensive network and customer loyalty programs to maintain pricing power. Additionally, its partnerships with health systems enhance its service offerings, providing a competitive advantage in integrated healthcare.
Changes in prescription drug pricing and reimbursement rates
Consumer health trends impacting pharmacy sales
Regulatory changes affecting pharmacy operations
Partnership developments with healthcare providers
Regulatory changes in the healthcare sector could impact profitability and operational practices.
Technological disruption from telehealth and online pharmacies may reduce foot traffic in retail locations.
Increased competition from online pharmacies and retail giants entering the healthcare space.
Market share loss to competitors with more aggressive pricing strategies.
High debt levels increase financial risk and limit flexibility in capital allocation.
Negative net margins raise concerns about long-term sustainability.
moderate - Walgreens' performance is somewhat linked to consumer spending and healthcare demand, which can be influenced by economic cycles.
The company's high debt levels (Debt/Equity of 4.04) mean that rising interest rates could increase financing costs, impacting profitability and cash flow.
high - Given the significant debt burden, Walgreens is sensitive to credit conditions, which could affect its refinancing options and overall financial stability.
value - Investors may be drawn to Walgreens due to its low valuation metrics (Price/Sales of 0.1x) despite operational challenges.
moderate - The stock has shown some volatility, with a 1-year return of 32.2%, indicating potential for both gains and losses.
